TO EVALUATE EFFICACY AND SAFETY PROFILE OF NIGELLA SATIVA AS ADD ON THERAPY IN PATIENTS OF CHRONIC KIDNEY DISEASE

EVALUATION OF EFFICACY AND SAFETY PROFILE OF NIGELLA SATIVA SUPPLEMENTATION IN PATIENTS OF CHRONIC KIDNEY DISEASE

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2015/01/005371

Enrollment

140

Registered

2015-01-07

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- CHRONIC KIDNEY DISEASE

Interventions

Intervention1: Test group: â?¢Tab. Torsemide 10 mg OD â?¢Tab. Telmisartan 40 mg OD â?¢Tab. Calcium carbonate 650 mg TDS â?¢Cap. Calcitriol 0.25 Î¼g OD â?¢Inj. Erytropoietin 2000U s.c. twice a week â?¢

Eligibility

Inclusion criteria

Inclusion criteria: Chronic kidney disease of different etiology, before ESRD. Patient not on dialysis.

Exclusion criteria

Exclusion criteria: Pregnancy Critically ill patient HIV/HBs Ag/Anti-HCV and immuno-compromised patient. Severe Renal pathology such as malignancy

Design outcomes

Primary

Measure	Time frame
Hb% Blood Urea Serum Creatinine (SCr) Blood Glucose- Fasting & Post Prandial 24 Hour Total Urine Protein (TUP) 24 Hour Total Urine Volume (TUV) Glomerular Filtration Rate(GFR)Timepoint: 0,6,12 WEEKS	—

Secondary

Measure	Time frame
LFTTimepoint: 0, 6 & 12 weeks of treatment	—

Countries

India

Contacts

Public ContactDR MOHAMMAD NASIRUDDIN

J.N. Medical College, A.M.U.

naseer_bettiah@yahoo.co.in09412596898

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026